CYP19A1 and breast cancer: The recognition that breast cancer eradication will require an understanding of the endocrine resistance mechanisms has led to innumerable lab-based studies (38, 39) to establish and analyze antiestrogen and aromatase inhibitor resistant breast cancer models.